Myovant Sciences Ltd. (NYSE:MYOV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On March21, 2018, Wayne DeVeydt, a member of the Board of Directors (the “Board”) of Myovant Sciences Ltd. (the “Company”), notified the Board that, as a result of his new position as Chief Executive Officer of Surgery Partners, Inc., a publicly traded company on the Nasdaq Global Select Market, he does not intend to stand for reelection at the Company’s 2018 Annual General Meeting of Shareholders (the “Annual Meeting”). Mr.DeVeydt’s term as director will, therefore, expire at the Annual Meeting. The Board thanks Mr.DeVeydt for his leadership and service to the Company and wishes him well in his new endeavor.
About Myovant Sciences Ltd. (NYSE:MYOV)
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.